Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature [15]

Leukemia

Volumn 21, Issue 6, 2007, Pages 1337-1338

  Nishii, K ^a   Nanbu, R ^a   Lorenzo, V F ^a   Monma, F ^a   Kato, K ^a   Ryuu, H ^a   Katayama, N ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; JANUS KINASE 2; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; CONTROLLED STUDY; GENE EXPRESSION; GENE FREQUENCY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; JAPAN; LETTER; LEUKEMIA CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 34249712934     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404626     Document Type: Letter

References (8)

1. Tefferi A, Pardanani A. Mutation screening for JAK2V617F: When to order the test and how to interpret the results. Leuk Res 2006; 30 739-744.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
3. Lorenzo F, Nishii K, Monma F, Kuwagata S, Usui E, Shiku H. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Leuk Res 2006; 30: 1235-1239.
4. Papayannopoulou T, Yokochi T, Nakamoto B, Martin P. The surface antigen profile of HEL cells. Prog Clin Biol Res 1983; 134: 277-292.
5. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370-3373.
6. Frohling S, Lipka DB, Kayser S, Scholl C, Schlenk RF, Dohner H et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006; 107: 1242-1243.
7. Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Lai JL et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067-2070.
8. Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359-2360.